Ultrasensitive interferons quantification reveals different cytokine profile secretion in inflammatory myopathies and can serve as biomarkers of activity in dermatomyositis

被引：0

作者：

Bolko, Lois ^{[1
,2
,3
]}

Anquetil, Celine ^{[2
,3
]}

Llibre, Alba ^{[4
]}

Maillard, Solene ^{[3
]}

Amelin, Damien ^{[3
]}

Dorgham, Karim ^{[5
]}

Bondet, Vincent ^{[4
]}

Landon-Cardinal, Oceane ^{[2
,6
,7
]}

Toquet, Segolene ^{[2
,3
]}

Mariampillai, Kuberaka ^{[2
]}

Malatre, Samuel ^{[3
]}

Mahoudeau, Alexandrine ^{[3
]}

Hervier, Baptiste ^{[2
]}

Rodero, Mathieu ^{[8
]}

Gorochov, Guy ^{[5
]}

Duffy, Darragh ^{[4
]}

Benveniste, Olivier ^{[2
,3
]}

Allenbach, Yves ^{[2
,3
]}

机构：

[1] Maison Blanche Hosp, Rheumatol, Reims, France

[2] Hop La Pitie Salpetriere, Natl Reference Ctr Rare NeuroMuscular Disorders, Dept Internal Med & Clin Immunol, Paris, France

[3] Sorbonne Univ, INSERM, Ctr Res Myol, Assoc Inst Myol, Paris, France

[4] Univ Paris Cite, Inst Pasteur, Translat Immunol Unit, Paris, France

[5] Sorbonne Univ, Hop Pitie Salpetriere, AP HP, INSERM,Ctr Immunol & Malad Infectieuses CIMI Paris, Paris, France

[6] Univ Montreal, Dept Med, Montreal, PQ, Canada

[7] CHU Montreal CHUM, Div Rheumatol, Montreal, PQ, Canada

[8] Paris Cite Univ, CNRS, Lab Pharmacol & Toxicol Chem & Biochem, Paris, France

来源：

FRONTIERS IN IMMUNOLOGY | 2025年 / 16卷

关键词：

interferon; dermatomyositis; immune mediated necrotizing myopathie; Anti-synthetase syndrom; inclusion body myositis; biomarker; INDUCIBLE GENE-EXPRESSION; DISEASE-ACTIVITY; CLASSIFICATION; CRITERIA; ADULT; NETHERLANDS; SIGNATURE; COLLEGE; PATHWAY; LEAGUE;

D O I：

10.3389/fimmu.2025.1529582

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Objective The objective of this study was to evaluate the presence of different types of interferon in idiopathic inflammatory myopathies (IIM) and their subgroups using ultrasensitive cytokine detection techniques (SIMOA) and to assess their potential as activity biomarkers. Methods Disease activity was measured at the time of serum collection and assessed by manual muscle testing eight (MMT8 score 0-150), muscle enzymes to calculate the Physician Global Assessment (PGA) (0-10). Patients were classified as active if PGA>5.Serum IFN-alpha and IFN-gamma levels was measured using the single molecule array (SIMOA) technique. Serum IFN-beta level was measured by Elisa. Correlation between IFN levels and disease activity were performed. Results We included 242 IIM patients and found a good correlation between type I Interferon (IFN) and dermatomyositis disease activity. IFN-alpha and IFN-beta was highly correlated with disease activity (r=0.76 and r=0,58). To evaluate whether the different types of Interferons could serve as biomarkers of activity, we generated ROC curves. Patients with active DM had a higher median IFN-alpha level (0.49 pg/ml [0.1-3.7]) compared with non-active patients (0.03 pg/ml [0.01-0.07] p<0.05). The area under the curve was 0.90 IC95 (0.76-0.97) p<0.05. Furthermore, Myositis-specific antibodies appear to be associated with a different secretion profile; patients with anti-MDA 5 antibodies had higher level of IFN-alpha than most other antibodies (6.58 vs 0.14 p<0.005). NXP2 had higher IFN-beta level than patients with Tif1 gamma antibodies. Conclusion Serum IFN-alpha level measured by SIMOA is a reliable biomarker of DM activity. Myositis-specific antibodies appear to be associated with a different secretion profile. This data needs to be confirmed in order to select the good therapeutics strategies in DM.

引用

页数：9